Lilly and Novo Nordisk’s battle for weight loss drugs reaches pharmacies
Weight loss drug Zepbound gains ground in the US against Novo Nordisk’s Wegovy. Lilly has about 40% market share in the U.S., reaching 130,000 prescriptions in the week ending July 19, compared to Wegovy’s 200,000, according to IQVIA data.
ENTRADAS POPULARES
Putin may discuss Ukraine peace deal with Trump
noviembre 22, 2024
Spain’s vice-president Ribera blames floods on climate change
noviembre 22, 2024
Storm lashes northwestern US, killing two people
noviembre 22, 2024
Iceland volcano erupts for tenth time in three years
noviembre 22, 2024
TRANSMISIÓN EN VIVO